# MDT Co-ordinators conference

Wed March 3<sup>rd</sup> Renaissance Hotel Heathrow

Derek Fawcett Consultant Urological Surgeon Royal Berkshire Hospital, Reading

President, British Association of Urological Surgeons


#### Prostate and bladder cancer

- What is it?
- How does it present?
- How do we make the diagnosis?
- How do we grade it?
- How do we stage it ?
- What are the treatment options in the MDT?

#### Prostate cancer

- Increasingly common with age
  - Familial inheritance in some
- Heterogeneous
  - [different tumours in the same prostate]
- Malignant transformation of prostatic glands
  - hence <u>ADENO</u>-carcinoma
  - ie gland forming

### Normal and malignant prostate



#### Presentation

- [Symptoms]
- PSA testing
- Rectal examination
- Symptoms of metastatic disease
  - Bone pain
  - paralysis

## Diagnosis


- Trans rectal biopsy under ultrasound [TRUS]
- Clinical picture + very high PSA

#### Grading of tumour [degree of malignancy]

- Gleason grade
- Dr. Donald F. Gleason, devised and, in 1966, first published the prostatic carcinoma grading system which bears his name.

#### **Gleason Grading System**

The Gleason Grading System is used to evaluate or "grade" prostate cancer cells obtained by needle biopsy. The cells are assigned a number between 1 and 5 — nearly normal cells are Grade 1 and the most abnormal are Grade 5. Then the scores of the two most common cell patterns are added together. Gleason scores range from 2 to 10. The higher the grade, the more aggressive the cancer.



## Tiger or pussy cat?

- Can we distinguish a cancer that threatens a man from one that does not?
  - Possibly
  - No certainty
- Temptation to err on the side of caution

# Staging [mapping]

- Is the tumour localised to the prostate?
- Are there secondaries?
- Options:
  - None [PSA <10]
  - Cross sectional imaging [MRI / CT]
  - Bone scanning [radio isotope scan]

## **MDT process**

- Review the clinical picture / history
- Co-morbidities
- Review histology [grade =/- stage]
- Review imaging
- Consensus on OPTIONS to put to patient
- Where treatment will be carried out and who by


# **OPTIONS**

- Active surveillance / watchful waiting
- Surgery
- Radiotherapy
  - EBRT
  - Brachytherapy
- Hormone therapy
- Combination




#### **Bladder cancer**

- Arises in urothelium
  - Bladder lining [transitional cells]
  - Hence "Transitional Cell Cancer" [TCC]
  - Environmental disease
- Strong link to pollution / **smoking**
- 80% superficial / papillary
- 20% muscle invasive / solid
- May affect all parts of urinary tract





#### Normal and papillary bladder cancer





#### CIS and muscle invasive





#### Presentation

- Almost always with HAEMATURIA
- VISIBLE : 20% risk of cancer
- INVISIBLE : 5% risk of cancer
- Dysuria / UTIs
  - Abnormal cytology

# Diagnosis

- Flexible cystoscopy
  - Look only / occasional biopsy
- Trans Urethral Resection Bladder Tumour
  - TURBT / TURT
- Resect /biopsy tumour and base of tumour to sample muscle
  - Muscle invasion is the single most important finding


# Grading [degree of malignancy]

- G1, G2, G3
  - Low grade [G1/G2]
  - Hi grade [G2/G3]

#### • BIOPSY may give STAGE if muscle is included

# Staging

- On biopsy
- CT urogram / ultrasound/ IVP
- Cross sectional imaging [CT/ MRI]



### **MDT process**

- Review histology [grade =/- stage]
- Review imaging
- Consensus on OPTIONS to put to patient
- Where treatment will be carried out and who by

### OPTIONS – non muscle invasive

- 3 month review cystoscopy [surveillance]
- Early re-resection for higher risk disease[T1/G3]
- Intravesical chemotherapy
  - Mitomycin C
  - BCG [others]
- Occasionally radical surgery

### **OPTIONS Carcinoma In Situ**

#### • BCG

• Radical surgery

### **OPTIONS : muscle invasive**

- Radical surgery
- Radiotherapy =/- neo-adjuvant [before] or adjuvant [after] chemotherapy

# QUESTIONS.....?

